Alzheimer's Disease Clinical Trials in New York

Showing 241-260 of 291 trials

Citalopram for Agitation in Alzheimer's Disease

NCT00898807

The purpose of this study is to evaluate the safety and efficacy of citalopram for agitation in Alzheimer's dementia.

JHSPH Center for Clinical Trials186 participantsStarted Jul 2009

Los Angeles, California, United States • Palo Alto, California, United States • Baltimore, Maryland, United States +5 more locations

COMPLETEDPhase 3< 1 mile

Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Carrier)

NCT00575055

This is a multicenter, double-blind, placebo controlled, randomized, outpatient, multiple dose study in male and female patients ages 50 to less than 89 years with mild to moderate AD. Approximately 200 study sites in the US and Canada will be involved. Patients will be randomized to receive either bapineuzumab or placebo. Each patient's participation will last approximately 1.5 years. Bapineuzumab is a humanized monoclonal antibody, which binds to and clears beta amyloid peptide, and is designed to provide antibodies to beta amyloid directly to the patient.

Alzheimer's Disease

JANSSEN Alzheimer Immunotherapy Research & Development, LLC1,121 participantsStarted Dec 2007

Birmingham, Alabama, United States • Goodyear, Arizona, United States • Phoenix, Arizona, United States +183 more locations

Citalopram for Agitation in Alzheimer's Disease

Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Carrier)

Alzheimer's Disease Trials in Other Cities

Intramuscular Aripiprazole in Acutely Agitated Patients Diagnosed With Dementia

Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type (ACTION) (Study Protocol CENA713DUS44, NCT00948766) and a 24 Week Open-label Extension to Study CENA713DUS44

A Randomized Study to Evaluate FK962 in Subjects With Mild to Moderate Alzheimer's Disease

Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease

Efficacy and Safety of T-817MA in Patients With Mild to Moderate Alzheimer's Disease

Comparative Efficacy, Safety, and Tolerability of Rivastigmine 10 and 15 cm^2 Patch in Patients With Alzheimer's Disease (AD) Showing Cognitive Decline

Randomized Trial of a Nutritional Supplement in Alzheimer's Disease

Phase III Study of the Correlation Between Florbetapir F18 PET Imaging and Amyloid Pathology in the Brain

Magnetic Resonance Spectroscopy Study of Memantine in Alzheimer's Disease

Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074 and Exploration of Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment - Prolonged Open Label Extension Phase

Assess the Prognostic Usefulness of Flutemetamol (18F) Injection for Identifying Subjects With Amnestic Mild Cognitive Impairment Who Will Convert to Clinically Probable Alzheimer's Disease

A Phase 3 Efficacy Study Of Dimebon In Patients With Moderate To Severe Alzheimer's Disease

VI-1121 for the Treatment Alzheimer's Disease

Safety and Efficacy Study of AC-3933 in Adults With Mild to Moderate Alzheimer's Disease

Preliminary Efficacy and Safety Study of ST101 in Alzheimer's Disease

A Randomized, Clinical Trial of Vitamin E and Memantine in Alzheimer's Disease

Proof of Concept Study of Cognitive Improvement in Patients With Alzheimer's Disease

Efficacy and Safety Study for Subjects With Mild-to-Moderate Alzheimer's Disease

Other Conditions in New York